While transplantation research continues to focus on the development of Treg-sparing and plasma cell/B-cell–targeting strategies to improve long-term outcomes, little attention has been paid to the emerging role of the TH17 cell in mediating chronic rejection. This review aimed to summarize the recent emergence of the TH17 and the newly described TH1/17 cell as major players in transplantation and to suggest ways of improving graft outcome through TH17-targeted immunosuppression.
1 Department of Surgery, Transplant Division, University of Wisconsin, Madison, WI.
2 Department of Surgery, Emory University Medical School, Atlanta, GA.
3 Address correspondence to: William J. Burlingham, Department of Surgery, University of Wisconsin, Madison, WI.
This work was supported by National Institutes of Health grant 1PO1AI084853-01, the EU-sponsored One Study, by a UW-Madison Department of Surgery Research grant (J.A.S. and W.J.B.), and by National Institutes of Health grant U19 AI051731 (A.B.A.).
The authors declare no conflicts of interest.
Received 24 April 2013. Revision requested 14 May 2013.
Accepted 29 August 2013.
Accepted November 8, 2013